SeaStar Medical is trading 5.3% lower at $3.40 in pre-market, with no direct company or market catalyst established. - Shares declined 6.75% to $3.59 on October 13. - No new company-specific announcement explaining the October 14 pre-market move was identified; the FDA breakthrough-device designation was announced October 7, not overnight. - The broader market is mixed ahead of September CPI, and major indexes are not showing a sharp same-direction decline.